ErbB2/Her2 Antikörper (AA 750-987)
-
- Target Alle ErbB2/Her2 Antikörper anzeigen
- ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
-
Bindungsspezifität
- AA 750-987
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser ErbB2/Her2 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- Aufreinigung
- Ascitic fluid
- Immunogen
- Purified recombinant fragment of human ERBB2(aa750-987) expressed in E. Coli.
- Klon
- 6C2
- Isotyp
- IgG1
- Top Product
- Discover our top product ErbB2/Her2 Primärantikörper
-
-
- Applikationshinweise
-
Western Bloting: 1/500 - 1/2000.
Immunohistochemistry: 1/200 - 1/1000.
Flow cytometry: 1/200 - 1/400.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test. - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C
-
-
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 19, Issue 8, pp. 2334-56, (2001) (PubMed).
: "Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 6, Issue 12, pp. 4745-54, (2001) (PubMed).
: "
-
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 19, Issue 8, pp. 2334-56, (2001) (PubMed).
-
- Target
- ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
- Andere Bezeichnung
- ERBB2 (ErbB2/Her2 Produkte)
- Synonyme
- CD340 antikoerper, HER-2 antikoerper, HER-2/neu antikoerper, HER2 antikoerper, MLN 19 antikoerper, NEU antikoerper, NGL antikoerper, TKR1 antikoerper, Erbb-2 antikoerper, Neu antikoerper, c-erbB2 antikoerper, c-neu antikoerper, mKIAA3023 antikoerper, wu:fv70f10 antikoerper, zgc:63601 antikoerper, erb2 antikoerper, erb-b2 receptor tyrosine kinase 2 antikoerper, ERBB2 antikoerper, Erbb2 antikoerper, erbb2 antikoerper
- Hintergrund
-
ERBB2: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian). This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Synonyms: NEU, HER2, TKR1, CD340, HER-2 - Molekulargewicht
- 180kDa
- Gen-ID
- 2064
- Pathways
- RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Skeletal Muscle Fiber Development
-